Immunic (IMUX)

Executive Summary

Immunic (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule therapies for chronic inflammatory and autoimmune diseases. Its lead asset, IMU-838 (vidofludimus calcium), is a selective oral DHODH inhibitor being investigated in multiple sclerosis (MS), ulcerative colitis, and other indications. The company has multiple active Phase 2 and Phase 3 trials in relapsing-remitting multiple sclerosis (RRMS), with Phase 3 enrollments ongoing. IMU-838 has shown favorable safety and efficacy signals in earlier studies, positioning it as a potential oral alternative to injectable MS therapies. Immunic also has preclinical programs targeting other immune pathways. With a market capitalization of ~$128 million, the company is at a pivotal juncture as it advances its lead candidate toward potential pivotal data readouts.

Upcoming Catalysts (preview)

• Q3 2025Phase 2 topline results for IMU-838 in RRMS (NCT05054140)60% success
• Q1 2026Completion of enrollment in Phase 3 CALLIPER trial (NCT05201638) in RRMS75% success
• H2 2026Upcoming data from Phase 2 IMU-838 trial in progressive MS (NCT03846219)50% success